Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Samantha Grossmith"'
Autor:
Alison, Laws, Ricardo, Pastorello, Tanujit, Dey, Samantha, Grossmith, Claire, King, Monica, McGrath, Stuart J, Schnitt, Elizabeth A, Mittendorf, Tari, King
Publikováno v:
Annals of Surgical Oncology. 29:7726-7736
Additional risk-stratification measures are needed in breast cancer patients with residual disease after neoadjuvant chemotherapy (NAC). We aimed to describe oncologic outcomes in a modern cohort treated with NAC, and evaluate the prognostic value of
Autor:
Anna Weiss, Claire King, Samantha Grossmith, Leah Portnow, Sughra Raza, Faina Nakhlis, Laura Dominici, Thanh Barbie, Christina Minami, Suniti Nimbkar, Esther Rhei, Elizabeth A. Mittendorf, Tari A. King
Publikováno v:
Annals of Surgical Oncology. 29:3764-3771
Prior studies examining sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) for cN1 patients have demonstrated that 20% of biopsied, clipped lymph nodes (cLNs) are nonsentinel lymph nodes (non-SLNs). Our goal was to determine how o
Autor:
Jessica Means, Tanujit Dey, Elizabeth A. Mittendorf, Jennifer R. Bellon, Olga Kantor, Samantha Grossmith, Tari A. King
Publikováno v:
Annals of Surgical Oncology. 29:972-980
Following publication of the AMAROS trial, we sought to optimize axillary lymph node dissection (ALND) or postmastectomy radiation therapy (PMRT) + axillary radiation (AxRT) utilization in cT1-2N0 patients with 1–2 positive sentinel lymph nodes (SL
Autor:
Ricardo G. Pastorello, Claire King, Samantha Grossmith, Tari A. King, Alison Laws, Stuart J. Schnitt, Monica McGrath, Elizabeth A. Mittendorf
Publikováno v:
Modern Pathology. 34:875-882
Among breast cancer patients treated with neoadjuvant chemotherapy (NAC) who do not experience a pathologic complete response (pCR), the pattern of residual disease in the breast varies. Pre-treatment clinico-pathologic features that predict the patt
Autor:
Samantha Grossmith, Anna Weiss, Olga Kantor, Stephanie M. Wong, Melia Wakeman, Alison Laws, Tari A. King, Elizabeth A. Mittendorf
Publikováno v:
Annals of Surgical Oncology. 28:1358-1367
Data to guide axillary management after neoadjuvant endocrine therapy (NET) remain limited. We analyzed type of axillary surgery [sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND)] and residual nodal disease burden after NET
Autor:
Alison, Laws, Ricardo, Pastorello, Tanujit, Dey, Samantha, Grossmith, Claire, King, Monica, McGrath, Stuart J, Schnitt, Elizabeth A, Mittendorf, Tari, King
Publikováno v:
Annals of Surgical Oncology. 29:7737-7738
Autor:
Anna Weiss, Sughra Raza, Elizabeth A. Mittendorf, Leah H. Portnow, Laura S. Dominici, Tari A. King, Samantha Grossmith, Faina Nakhlis, Claire King
Publikováno v:
Cancer Research. 81:PD4-06
Objectives and Rationale: For breast cancer patients receiving neoadjuvant chemotherapy (NAC) and undergoing pre-NAC axillary lymph node biopsy, NCCN guidelines recommend biopsy marker (clip) placement. This recommendation is based on reports that re
Autor:
Anna Weiss, Claire King, Samantha Grossmith, Leah Portnow, Sughra Raza, Faina Nakhlis, Laura Dominici, Thanh Barbie, Christina Minami, Suniti Nimbkar, Esther Rhei, Elizabeth A. Mittendorf, Tari A. King
Publikováno v:
Annals of Surgical Oncology. 29:3774-3775
Autor:
Olga, Kantor, Jessica, Means, Samantha, Grossmith, Tanujit, Dey, Jennifer R, Bellon, Elizabeth A, Mittendorf, Tari A, King
Publikováno v:
Annals of surgical oncology. 29(2)
Following publication of the AMAROS trial, we sought to optimize axillary lymph node dissection (ALND) or postmastectomy radiation therapy (PMRT) + axillary radiation (AxRT) utilization in cT1-2N0 patients with 1-2 positive sentinel lymph nodes (SLNs
Autor:
Ricardo G, Pastorello, Alison, Laws, Samantha, Grossmith, Claire, King, Monica, McGrath, Elizabeth A, Mittendorf, Tari A, King, Stuart J, Schnitt
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 34(5)
Among breast cancer patients treated with neoadjuvant chemotherapy (NAC) who do not experience a pathologic complete response (pCR), the pattern of residual disease in the breast varies. Pre-treatment clinico-pathologic features that predict the patt